TCM Biotech International Corp.

As of June 30, 2026, TCM Biotech International Corp. carries a market capitalization of 14.45B, placing it among publicly traded companies globally. Its enterprise value stands at 13.28B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, TCM Biotech International Corp. has 66.43M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 38.02, and the price-to-book ratio stands at 7.39.

These figures are as of June 30, 2026. The EV/Sales ratio of 37.51 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 13.28B versus a market cap of 14.45B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, TCM Biotech International Corp. maintains a current ratio of 11.68, meaning it holds 11.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.27, indicating moderate leverage, while an interest coverage ratio of -107.99 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, TCM Biotech International Corp. posted a negative return on equity (ROE) of -2.31, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -2.10, reflecting losses generated across the asset base. The company generates approximately 2.81M in revenue per employee across its workforce of 126.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.26 indicates how many times TCM Biotech International Corp. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, TCM Biotech International Corp. recorded 49,000.00 in income tax expense. The company reported a pretax loss of -34.77M and -34.82M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

These figures are as of the close on October 22, 2026.

Over the twelve months ended June 30, 2026, TCM Biotech International Corp. generated 353.98M in revenue and converted that into -34.82M in net income, yielding earnings per share of -0.56. EBITDA reached -27.65M, while operating income came in at -38.29M.

As of June 30, 2026, TCM Biotech International Corp. holds 1.20B in cash and equivalents against 24.88M in total debt, resulting in a net debt position of -878.80M. Total book value stands at 1.95B, with working capital of 1.43B providing operational flexibility.

TCM Biotech International Corp. produced -49.19M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -892,000.00 in capital expenditures, free cash flow totaled -50.08M - equivalent to -0.81 per share.

Over the twelve months ended June 30, 2026, TCM Biotech International Corp. posted a gross margin of 45.91, reflecting its pricing power and cost economics. The operating margin of -10.82 and net profit margin of -9.84 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -0.37: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -6.52, meaning TCM Biotech International Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

TCM Biotech International Corp.'s most recent stock split took place on July 20, 2023.

As of June 30, 2026, TCM Biotech International Corp. has an Altman Z-Score of 58.77, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.